News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 15, 2026 at 14:11 Big Tech Stable Warm

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Jonathan M. Gitlin Original source
What’s the deal with Alzheimer’s disease and amyloid?

At the end of last month, a scientific journal pulled a research paper on Alzheimer's disease. The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer's disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication. But this wasn't an isolated case. Over the past few years, multiple studies arguing that amyloid-β is the central driver of Alzheimer's disease have been retracted. Some scientists have even been indicted for fraud over the issue. All the while, none of the drugs targeting this protein and its pathway have had any real clinical effect. Read full article Comments

Stay on the signal

Follow What’s the deal with Alzheimer’s disease and amyloid?

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Alzheimer, Amyloid, and Ars Technica, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 13, 2026 at 11:18 Ars Technica

Threads of underground fungal networks are long enough to reach beyond the Solar System

Researchers have quantified the length and mass of arbuscular mycorrhizal fungal networks globally.

Jun 13, 2026 at 03:00 Ars Technica

Anthropic shuts down Fable, Mythos models following Trump admin directive

Commerce dept. worries that a Fable 5 "jailbreak" could be a national security threat.

Jun 12, 2026 at 22:20 Ars Technica

SpaceX is now a public company valued for its AI potential, so what comes next?

As of today, SpaceX is owned by investors who will want to see it make money.

Jun 12, 2026 at 19:26 Ars Technica

PeopleSoft 0-day affecting hundreds of organizations steals gigabytes of data

Vulnerability in the Oracle-owned PeopleSoft software is about as critical as they come.

Jun 12, 2026 at 18:57 Ars Technica

Controversial FISA spying law expires tonight. The spying will continue.

Section 702 of FISA to expire tonight, but certification lasts until March 2027.

Apr 15, 2026 at 14:11 Ars Technica

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page